Peter Gottlieb
Concepts (593)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 143 | 2025 | 3697 | 6.790 |
Why?
| | Insulin | 52 | 2025 | 2389 | 2.680 |
Why?
| | C-Peptide | 32 | 2025 | 161 | 2.130 |
Why?
| | Islets of Langerhans | 24 | 2025 | 803 | 1.880 |
Why?
| | Autoantibodies | 38 | 2025 | 1498 | 1.700 |
Why?
| | Insulin-Secreting Cells | 18 | 2021 | 372 | 1.600 |
Why?
| | Hypoglycemic Agents | 21 | 2024 | 1282 | 1.480 |
Why?
| | B-Lymphocytes | 10 | 2025 | 844 | 1.180 |
Why?
| | Antilymphocyte Serum | 8 | 2021 | 64 | 1.000 |
Why?
| | T-Lymphocytes | 25 | 2025 | 1996 | 1.000 |
Why?
| | CD4-Positive T-Lymphocytes | 14 | 2025 | 1092 | 0.980 |
Why?
| | Autoantigens | 15 | 2021 | 429 | 0.960 |
Why?
| | Monitoring, Ambulatory | 4 | 2010 | 86 | 0.950 |
Why?
| | Blood Glucose | 17 | 2025 | 2161 | 0.940 |
Why?
| | Autoimmunity | 19 | 2023 | 893 | 0.910 |
Why?
| | Antibodies, Monoclonal, Humanized | 12 | 2023 | 803 | 0.830 |
Why?
| | Proinsulin | 7 | 2024 | 52 | 0.800 |
Why?
| | Clinical Trials as Topic | 12 | 2025 | 1037 | 0.780 |
Why?
| | Immunosuppressive Agents | 9 | 2023 | 886 | 0.770 |
Why?
| | Blood Glucose Self-Monitoring | 4 | 2010 | 629 | 0.680 |
Why?
| | Adolescent | 75 | 2025 | 21402 | 0.680 |
Why?
| | Addison Disease | 8 | 2012 | 43 | 0.670 |
Why?
| | Humans | 163 | 2025 | 136899 | 0.650 |
Why?
| | Adult | 91 | 2025 | 37595 | 0.640 |
Why?
| | CD4 Antigens | 2 | 2013 | 141 | 0.640 |
Why?
| | Immunologic Factors | 7 | 2019 | 239 | 0.640 |
Why?
| | Child | 68 | 2025 | 21896 | 0.610 |
Why?
| | Preventive Medicine | 2 | 2018 | 43 | 0.610 |
Why?
| | Polyendocrinopathies, Autoimmune | 3 | 2010 | 18 | 0.600 |
Why?
| | Prediabetic State | 7 | 2018 | 247 | 0.600 |
Why?
| | Diabetes Mellitus, Type 2 | 6 | 2020 | 2508 | 0.580 |
Why?
| | Young Adult | 48 | 2025 | 13157 | 0.560 |
Why?
| | Peptide Fragments | 13 | 2024 | 707 | 0.560 |
Why?
| | Insulin Antibodies | 6 | 2022 | 105 | 0.550 |
Why?
| | Granulocyte Colony-Stimulating Factor | 6 | 2021 | 74 | 0.530 |
Why?
| | CD8-Positive T-Lymphocytes | 10 | 2019 | 916 | 0.530 |
Why?
| | HLA-DQ Antigens | 11 | 2019 | 181 | 0.520 |
Why?
| | Immunotherapy | 5 | 2024 | 645 | 0.510 |
Why?
| | Mycophenolic Acid | 3 | 2012 | 113 | 0.490 |
Why?
| | Chromogranin A | 2 | 2024 | 42 | 0.470 |
Why?
| | Peptides | 5 | 2024 | 981 | 0.470 |
Why?
| | Autoimmune Diseases | 10 | 2017 | 459 | 0.460 |
Why?
| | Steroid 21-Hydroxylase | 5 | 2012 | 30 | 0.460 |
Why?
| | Female | 93 | 2025 | 72703 | 0.460 |
Why?
| | Monocytes | 4 | 2016 | 567 | 0.460 |
Why?
| | Male | 85 | 2025 | 67308 | 0.450 |
Why?
| | Immunoglobulin G | 6 | 2018 | 886 | 0.450 |
Why?
| | Glutamate Decarboxylase | 9 | 2022 | 170 | 0.450 |
Why?
| | Mice, Inbred NOD | 16 | 2023 | 601 | 0.440 |
Why?
| | Biomarkers | 13 | 2024 | 4148 | 0.430 |
Why?
| | Cytokines | 9 | 2018 | 2078 | 0.430 |
Why?
| | Vaccines, DNA | 1 | 2013 | 31 | 0.420 |
Why?
| | Cystic Fibrosis | 3 | 2012 | 1088 | 0.410 |
Why?
| | Interferon-gamma | 6 | 2021 | 790 | 0.400 |
Why?
| | Myeloid Cells | 1 | 2014 | 146 | 0.400 |
Why?
| | alpha 1-Antitrypsin | 1 | 2014 | 108 | 0.400 |
Why?
| | Immunomodulation | 1 | 2013 | 98 | 0.390 |
Why?
| | T-Lymphocyte Subsets | 8 | 2018 | 425 | 0.390 |
Why?
| | Immunologic Memory | 7 | 2019 | 368 | 0.390 |
Why?
| | Hypoglycemia | 6 | 2009 | 442 | 0.370 |
Why?
| | Disease Progression | 16 | 2021 | 2744 | 0.360 |
Why?
| | Dendritic Cells | 2 | 2014 | 488 | 0.360 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 346 | 0.350 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 4 | 2021 | 63 | 0.340 |
Why?
| | Diabetes Mellitus | 2 | 2023 | 1033 | 0.330 |
Why?
| | Histocompatibility Antigens Class I | 6 | 2011 | 203 | 0.320 |
Why?
| | CD3 Complex | 5 | 2019 | 106 | 0.320 |
Why?
| | Immunoconjugates | 4 | 2014 | 116 | 0.320 |
Why?
| | HLA-DR3 Antigen | 5 | 2022 | 80 | 0.310 |
Why?
| | HLA-DR Antigens | 8 | 2018 | 228 | 0.310 |
Why?
| | Area Under Curve | 9 | 2024 | 316 | 0.310 |
Why?
| | Lymphocyte Activation | 7 | 2025 | 1150 | 0.310 |
Why?
| | Clonal Anergy | 3 | 2018 | 52 | 0.290 |
Why?
| | Insulin, Regular, Human | 3 | 2024 | 43 | 0.280 |
Why?
| | Antibodies, Monoclonal | 5 | 2010 | 1417 | 0.280 |
Why?
| | Hearing Aids | 2 | 2021 | 79 | 0.280 |
Why?
| | Cation Transport Proteins | 3 | 2017 | 134 | 0.270 |
Why?
| | Toll-Like Receptors | 3 | 2014 | 186 | 0.270 |
Why?
| | Age of Onset | 6 | 2020 | 520 | 0.260 |
Why?
| | Tympanic Membrane | 2 | 2017 | 25 | 0.250 |
Why?
| | Zinc Transporter 8 | 4 | 2021 | 87 | 0.250 |
Why?
| | Double-Blind Method | 12 | 2021 | 1980 | 0.250 |
Why?
| | Regeneration | 2 | 2017 | 194 | 0.250 |
Why?
| | Receptors, Interleukin-2 | 2 | 2006 | 66 | 0.250 |
Why?
| | Time Factors | 10 | 2020 | 6802 | 0.250 |
Why?
| | Animals | 33 | 2024 | 36915 | 0.240 |
Why?
| | Glucose Tolerance Test | 6 | 2025 | 353 | 0.230 |
Why?
| | Protein Precursors | 3 | 2016 | 132 | 0.230 |
Why?
| | Middle Aged | 36 | 2025 | 33118 | 0.230 |
Why?
| | Genetic Predisposition to Disease | 10 | 2025 | 2416 | 0.230 |
Why?
| | Insulin, Isophane | 1 | 2004 | 21 | 0.230 |
Why?
| | Antigen Presentation | 3 | 2018 | 216 | 0.230 |
Why?
| | Child, Preschool | 21 | 2025 | 11013 | 0.220 |
Why?
| | T-Lymphocytes, Regulatory | 6 | 2023 | 392 | 0.220 |
Why?
| | Software | 2 | 2008 | 670 | 0.220 |
Why?
| | Precision Medicine | 3 | 2023 | 413 | 0.220 |
Why?
| | Mice | 25 | 2024 | 17775 | 0.220 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 3 | 2013 | 88 | 0.210 |
Why?
| | Temporal Bone | 2 | 2021 | 52 | 0.210 |
Why?
| | Pregnancy in Diabetics | 2 | 2003 | 123 | 0.210 |
Why?
| | Immunotherapy, Active | 2 | 2014 | 9 | 0.200 |
Why?
| | Diabetic Ketoacidosis | 2 | 2024 | 202 | 0.200 |
Why?
| | Plasmids | 3 | 2013 | 363 | 0.200 |
Why?
| | Histocompatibility Testing | 4 | 2013 | 126 | 0.200 |
Why?
| | Polyethylene Glycols | 3 | 2018 | 640 | 0.190 |
Why?
| | Interleukin-1beta | 3 | 2014 | 371 | 0.190 |
Why?
| | Islets of Langerhans Transplantation | 2 | 2015 | 64 | 0.190 |
Why?
| | Epitopes, T-Lymphocyte | 4 | 2011 | 187 | 0.190 |
Why?
| | Treatment Outcome | 12 | 2024 | 10768 | 0.190 |
Why?
| | Lymphocyte Depletion | 2 | 2013 | 135 | 0.190 |
Why?
| | Body Weight | 2 | 2025 | 973 | 0.190 |
Why?
| | Haplotypes | 6 | 2022 | 487 | 0.190 |
Why?
| | Immune Tolerance | 2 | 2017 | 362 | 0.190 |
Why?
| | Methyldopa | 2 | 2019 | 7 | 0.190 |
Why?
| | Recombinant Fusion Proteins | 2 | 2015 | 664 | 0.180 |
Why?
| | Round Window, Ear | 1 | 2021 | 17 | 0.180 |
Why?
| | Imatinib Mesylate | 1 | 2021 | 79 | 0.180 |
Why?
| | Receptors, Antigen, T-Cell | 5 | 2022 | 719 | 0.180 |
Why?
| | Necrobiosis Lipoidica | 1 | 2001 | 2 | 0.180 |
Why?
| | Hyperglycemia | 1 | 2024 | 344 | 0.180 |
Why?
| | Asymptomatic Diseases | 1 | 2021 | 87 | 0.180 |
Why?
| | Histocompatibility Antigens Class II | 3 | 2011 | 368 | 0.170 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2001 | 91 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2019 | 2066 | 0.170 |
Why?
| | History, 21st Century | 2 | 2018 | 211 | 0.170 |
Why?
| | Administration, Oral | 2 | 2024 | 811 | 0.170 |
Why?
| | History, 20th Century | 2 | 2018 | 324 | 0.170 |
Why?
| | Biomarkers, Pharmacological | 1 | 2020 | 28 | 0.160 |
Why?
| | Interleukin-7 Receptor alpha Subunit | 1 | 2019 | 12 | 0.160 |
Why?
| | Biological Variation, Population | 1 | 2019 | 22 | 0.160 |
Why?
| | Acoustic Stimulation | 1 | 2021 | 340 | 0.160 |
Why?
| | Cytomegalovirus | 2 | 2018 | 160 | 0.160 |
Why?
| | Glucagon-Like Peptides | 1 | 2020 | 55 | 0.160 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2025 | 2175 | 0.160 |
Why?
| | Hepatitis Delta Virus | 3 | 1994 | 7 | 0.160 |
Why?
| | Epitopes | 5 | 2024 | 479 | 0.160 |
Why?
| | Luminescence | 2 | 2016 | 38 | 0.160 |
Why?
| | Graves Disease | 2 | 2017 | 34 | 0.160 |
Why?
| | Th2 Cells | 2 | 2014 | 176 | 0.160 |
Why?
| | Mass Screening | 2 | 2025 | 1262 | 0.150 |
Why?
| | Forkhead Transcription Factors | 3 | 2016 | 191 | 0.150 |
Why?
| | Gastrointestinal Microbiome | 2 | 2018 | 689 | 0.150 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2025 | 1460 | 0.150 |
Why?
| | Family | 3 | 2025 | 667 | 0.150 |
Why?
| | Cytoprotection | 1 | 2018 | 56 | 0.150 |
Why?
| | Viral Proteins | 3 | 1997 | 346 | 0.150 |
Why?
| | Immunity, Cellular | 2 | 2018 | 267 | 0.140 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2017 | 15 | 0.140 |
Why?
| | Biomedical Research | 2 | 2018 | 688 | 0.140 |
Why?
| | Hearing Loss | 1 | 2021 | 221 | 0.140 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 1990 | 192 | 0.140 |
Why?
| | HLA-A2 Antigen | 1 | 2017 | 48 | 0.140 |
Why?
| | Twins, Dizygotic | 1 | 2018 | 183 | 0.140 |
Why?
| | Abatacept | 5 | 2023 | 53 | 0.140 |
Why?
| | HLA-DR4 Antigen | 4 | 2022 | 78 | 0.140 |
Why?
| | Twins, Monozygotic | 1 | 2018 | 213 | 0.140 |
Why?
| | Inflammation | 4 | 2018 | 2817 | 0.140 |
Why?
| | Thyroid Gland | 1 | 2017 | 94 | 0.140 |
Why?
| | Antibody-Producing Cells | 1 | 2017 | 30 | 0.140 |
Why?
| | Treatment Failure | 1 | 2018 | 353 | 0.140 |
Why?
| | Heparin-binding EGF-like Growth Factor | 1 | 2017 | 16 | 0.140 |
Why?
| | Magnetic Fields | 1 | 2017 | 24 | 0.130 |
Why?
| | Tympanic Membrane Perforation | 1 | 2017 | 17 | 0.130 |
Why?
| | Th1 Cells | 2 | 2009 | 143 | 0.130 |
Why?
| | Cell Separation | 2 | 2017 | 319 | 0.130 |
Why?
| | Cytomegalovirus Infections | 1 | 2018 | 194 | 0.130 |
Why?
| | Dysbiosis | 1 | 2018 | 179 | 0.130 |
Why?
| | Antibody Formation | 1 | 2018 | 299 | 0.130 |
Why?
| | Influenza, Human | 1 | 2022 | 626 | 0.130 |
Why?
| | Trans-Activators | 1 | 1998 | 399 | 0.130 |
Why?
| | Follow-Up Studies | 8 | 2021 | 5126 | 0.130 |
Why?
| | Risk Factors | 13 | 2025 | 10313 | 0.120 |
Why?
| | RNA, Catalytic | 2 | 1994 | 186 | 0.120 |
Why?
| | Photochemotherapy | 1 | 1995 | 36 | 0.120 |
Why?
| | Trypanosoma cruzi | 1 | 1995 | 39 | 0.120 |
Why?
| | Tuftsin | 3 | 1983 | 4 | 0.120 |
Why?
| | Host-Pathogen Interactions | 1 | 2018 | 367 | 0.120 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 919 | 0.120 |
Why?
| | Cross-Sectional Studies | 7 | 2025 | 5398 | 0.110 |
Why?
| | Homeodomain Proteins | 1 | 1998 | 504 | 0.110 |
Why?
| | Dermatologic Agents | 1 | 2015 | 69 | 0.110 |
Why?
| | Genes, Viral | 4 | 1992 | 88 | 0.110 |
Why?
| | Drug Therapy, Combination | 3 | 2018 | 1060 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 3 | 2022 | 337 | 0.110 |
Why?
| | Law Enforcement | 1 | 2014 | 40 | 0.110 |
Why?
| | Nanoparticles | 2 | 2017 | 483 | 0.110 |
Why?
| | Phenotype | 2 | 2019 | 3201 | 0.110 |
Why?
| | Crime | 1 | 2014 | 60 | 0.110 |
Why?
| | Cochlear Implants | 1 | 2015 | 110 | 0.110 |
Why?
| | RNA, Viral | 4 | 1992 | 651 | 0.110 |
Why?
| | Criminals | 1 | 2014 | 36 | 0.100 |
Why?
| | Graft Rejection | 2 | 2015 | 623 | 0.100 |
Why?
| | Withholding Treatment | 1 | 2013 | 72 | 0.100 |
Why?
| | Primary Cell Culture | 1 | 2013 | 172 | 0.100 |
Why?
| | Transglutaminases | 1 | 2013 | 156 | 0.100 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2013 | 225 | 0.100 |
Why?
| | Adjuvants, Immunologic | 1 | 2014 | 226 | 0.100 |
Why?
| | Gene Expression | 2 | 2013 | 1505 | 0.100 |
Why?
| | Pancreatectomy | 1 | 2015 | 249 | 0.100 |
Why?
| | Adaptive Immunity | 1 | 2013 | 164 | 0.100 |
Why?
| | Reproducibility of Results | 3 | 2009 | 3282 | 0.100 |
Why?
| | Nucleic Acid Conformation | 3 | 1994 | 720 | 0.090 |
Why?
| | Communicable Diseases | 1 | 2014 | 160 | 0.090 |
Why?
| | DNA, Viral | 1 | 1994 | 359 | 0.090 |
Why?
| | Sensitivity and Specificity | 2 | 2009 | 1945 | 0.090 |
Why?
| | Diabetic Angiopathies | 2 | 2010 | 258 | 0.090 |
Why?
| | Receptors, Immunologic | 2 | 1983 | 223 | 0.090 |
Why?
| | Amino Acid Sequence | 9 | 2015 | 2143 | 0.090 |
Why?
| | RNA Phages | 2 | 1988 | 2 | 0.090 |
Why?
| | Flow Cytometry | 4 | 2019 | 1185 | 0.090 |
Why?
| | Proportional Hazards Models | 3 | 2021 | 1262 | 0.090 |
Why?
| | Thyroiditis | 1 | 1991 | 4 | 0.090 |
Why?
| | Alleles | 5 | 2011 | 888 | 0.090 |
Why?
| | Polymorphism, Genetic | 3 | 2010 | 652 | 0.090 |
Why?
| | Down-Regulation | 1 | 2014 | 658 | 0.090 |
Why?
| | Herpesviridae Infections | 1 | 2012 | 148 | 0.090 |
Why?
| | Lymphocyte Count | 3 | 2019 | 150 | 0.090 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2012 | 99 | 0.090 |
Why?
| | Cells, Cultured | 7 | 2017 | 4204 | 0.090 |
Why?
| | Recombinant Proteins | 3 | 2018 | 1357 | 0.090 |
Why?
| | HLA-B Antigens | 1 | 2011 | 62 | 0.090 |
Why?
| | RNA, Double-Stranded | 2 | 1988 | 56 | 0.090 |
Why?
| | Organophosphorus Compounds | 1 | 2011 | 80 | 0.090 |
Why?
| | Cryopreservation | 1 | 2011 | 96 | 0.090 |
Why?
| | Glycine | 1 | 2011 | 175 | 0.090 |
Why?
| | Endocrine Cells | 1 | 2010 | 7 | 0.090 |
Why?
| | Interleukin-6 | 2 | 2012 | 771 | 0.090 |
Why?
| | Pilot Projects | 3 | 2021 | 1684 | 0.090 |
Why?
| | Transplantation Immunology | 1 | 1990 | 34 | 0.080 |
Why?
| | Molecular Sequence Data | 9 | 2015 | 2901 | 0.080 |
Why?
| | Drug Delivery Systems | 1 | 2013 | 362 | 0.080 |
Why?
| | Insulin, Long-Acting | 3 | 2004 | 63 | 0.080 |
Why?
| | HLA Antigens | 4 | 2022 | 237 | 0.080 |
Why?
| | Inflammation Mediators | 2 | 2010 | 514 | 0.080 |
Why?
| | Insulin Glargine | 3 | 2004 | 84 | 0.080 |
Why?
| | Single-Cell Analysis | 2 | 2025 | 309 | 0.080 |
Why?
| | Genotype | 5 | 2015 | 1906 | 0.080 |
Why?
| | Muromonab-CD3 | 1 | 2009 | 20 | 0.080 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 2009 | 173 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 4 | 2014 | 849 | 0.080 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2012 | 142 | 0.080 |
Why?
| | Mental Health Services | 1 | 2014 | 409 | 0.080 |
Why?
| | Antigens | 3 | 2023 | 358 | 0.080 |
Why?
| | Receptors, Chemokine | 2 | 2007 | 47 | 0.080 |
Why?
| | Prognosis | 4 | 2021 | 4011 | 0.080 |
Why?
| | Interleukin-17 | 1 | 2009 | 120 | 0.080 |
Why?
| | Calcinosis | 1 | 2010 | 233 | 0.070 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 182 | 0.070 |
Why?
| | Bacteria | 1 | 2015 | 855 | 0.070 |
Why?
| | Immunodominant Epitopes | 2 | 2006 | 28 | 0.070 |
Why?
| | Insulin Infusion Systems | 2 | 2004 | 391 | 0.070 |
Why?
| | Remission Induction | 2 | 2018 | 286 | 0.070 |
Why?
| | Platelet Membrane Glycoprotein IIb | 1 | 2007 | 4 | 0.070 |
Why?
| | Enzyme-Linked Immunospot Assay | 3 | 2011 | 36 | 0.070 |
Why?
| | Regression Analysis | 1 | 2010 | 1026 | 0.070 |
Why?
| | Homicide | 1 | 1988 | 66 | 0.070 |
Why?
| | Hydrocortisone | 2 | 2012 | 317 | 0.070 |
Why?
| | Equipment Design | 1 | 2009 | 523 | 0.070 |
Why?
| | Consensus | 2 | 2023 | 678 | 0.070 |
Why?
| | Safety | 1 | 2009 | 341 | 0.070 |
Why?
| | Radioimmunoassay | 2 | 2017 | 174 | 0.070 |
Why?
| | Case-Control Studies | 5 | 2016 | 3528 | 0.070 |
Why?
| | Risk Assessment | 3 | 2025 | 3432 | 0.070 |
Why?
| | CD40 Antigens | 1 | 2007 | 89 | 0.070 |
Why?
| | Rituximab | 3 | 2013 | 172 | 0.070 |
Why?
| | Microsatellite Repeats | 2 | 2009 | 168 | 0.060 |
Why?
| | Receptors, Interleukin-7 | 1 | 2006 | 28 | 0.060 |
Why?
| | Disease Models, Animal | 2 | 2009 | 4281 | 0.060 |
Why?
| | Killer Cells, Natural | 2 | 2016 | 444 | 0.060 |
Why?
| | Bacteriophages | 1 | 1988 | 94 | 0.060 |
Why?
| | CD4 Lymphocyte Count | 3 | 2015 | 270 | 0.060 |
Why?
| | Mutation | 5 | 2015 | 3948 | 0.060 |
Why?
| | Hybridomas | 2 | 2004 | 237 | 0.060 |
Why?
| | Atherosclerosis | 1 | 2010 | 411 | 0.060 |
Why?
| | Infant | 5 | 2024 | 9408 | 0.060 |
Why?
| | Isoenzymes | 2 | 2004 | 305 | 0.060 |
Why?
| | Diabetic Retinopathy | 2 | 2005 | 187 | 0.060 |
Why?
| | Proteins | 2 | 2018 | 1012 | 0.060 |
Why?
| | Disease Susceptibility | 2 | 2019 | 344 | 0.060 |
Why?
| | Protein Tyrosine Phosphatases | 2 | 2004 | 168 | 0.060 |
Why?
| | Gene Frequency | 3 | 2016 | 521 | 0.060 |
Why?
| | Mental Disorders | 1 | 2014 | 1080 | 0.060 |
Why?
| | Chemokines, CXC | 1 | 2005 | 70 | 0.060 |
Why?
| | Signal Transduction | 3 | 2019 | 5077 | 0.060 |
Why?
| | Risk | 3 | 2019 | 905 | 0.060 |
Why?
| | Urban Population | 1 | 1988 | 470 | 0.060 |
Why?
| | Prevalence | 3 | 2024 | 2709 | 0.060 |
Why?
| | Acetamides | 1 | 2005 | 36 | 0.060 |
Why?
| | Major Histocompatibility Complex | 2 | 2002 | 231 | 0.060 |
Why?
| | Exanthema | 2 | 2019 | 77 | 0.060 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2025 | 130 | 0.060 |
Why?
| | Blood Coagulation Factors | 1 | 1984 | 54 | 0.060 |
Why?
| | Coronary Artery Disease | 1 | 2010 | 701 | 0.050 |
Why?
| | Immunophenotyping | 2 | 2018 | 318 | 0.050 |
Why?
| | Immunoglobulin Fragments | 1 | 1983 | 12 | 0.050 |
Why?
| | Feces | 2 | 2018 | 477 | 0.050 |
Why?
| | Base Sequence | 6 | 1994 | 2180 | 0.050 |
Why?
| | Niacinamide | 1 | 2004 | 79 | 0.050 |
Why?
| | Genes, MHC Class II | 2 | 2002 | 74 | 0.050 |
Why?
| | Placebos | 2 | 2013 | 207 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 2 | 2019 | 557 | 0.050 |
Why?
| | Age Factors | 3 | 2017 | 3290 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 379 | 0.050 |
Why?
| | Immunoassay | 1 | 2003 | 114 | 0.050 |
Why?
| | Genetic Association Studies | 1 | 2025 | 377 | 0.050 |
Why?
| | Cell Survival | 2 | 2019 | 1122 | 0.050 |
Why?
| | Tissue Donors | 1 | 2006 | 414 | 0.050 |
Why?
| | Interleukin-4 | 2 | 2002 | 217 | 0.050 |
Why?
| | Antigens, CD1 | 1 | 2002 | 59 | 0.050 |
Why?
| | Mice, Knockout | 1 | 2009 | 2998 | 0.050 |
Why?
| | Siblings | 2 | 2018 | 228 | 0.050 |
Why?
| | Receptors, CXCR3 | 2 | 2016 | 16 | 0.050 |
Why?
| | Antibody Affinity | 2 | 2016 | 60 | 0.050 |
Why?
| | Cloning, Molecular | 3 | 2014 | 536 | 0.050 |
Why?
| | Cell Differentiation | 1 | 2009 | 1976 | 0.050 |
Why?
| | Canada | 2 | 2014 | 417 | 0.050 |
Why?
| | Denmark | 2 | 2014 | 46 | 0.050 |
Why?
| | Preconception Care | 1 | 2002 | 43 | 0.050 |
Why?
| | Diseases in Twins | 2 | 2018 | 175 | 0.050 |
Why?
| | Labor, Obstetric | 1 | 2002 | 61 | 0.050 |
Why?
| | Pyrimidines | 1 | 2005 | 472 | 0.050 |
Why?
| | Cell Proliferation | 2 | 2009 | 2471 | 0.050 |
Why?
| | Reference Values | 3 | 2009 | 820 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2001 | 37 | 0.040 |
Why?
| | Pancreas | 2 | 2018 | 328 | 0.040 |
Why?
| | Algorithms | 1 | 2008 | 1695 | 0.040 |
Why?
| | Administration, Topical | 1 | 2001 | 149 | 0.040 |
Why?
| | Pregnancy Outcome | 1 | 2003 | 410 | 0.040 |
Why?
| | Venoms | 1 | 2020 | 29 | 0.040 |
Why?
| | Vitamin D | 1 | 2004 | 392 | 0.040 |
Why?
| | DNA | 4 | 1994 | 1460 | 0.040 |
Why?
| | Rats, Inbred BB | 2 | 1991 | 6 | 0.040 |
Why?
| | Bacterial Proteins | 2 | 2018 | 889 | 0.040 |
Why?
| | Kinetics | 4 | 1994 | 1679 | 0.040 |
Why?
| | Diagnostic Techniques, Endocrine | 1 | 2020 | 14 | 0.040 |
Why?
| | HLA-DR2 Antigen | 1 | 1999 | 7 | 0.040 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2019 | 82 | 0.040 |
Why?
| | Antibodies, Heterophile | 1 | 1999 | 14 | 0.040 |
Why?
| | Membrane Proteins | 2 | 2004 | 1167 | 0.040 |
Why?
| | HLA-DRB1 Chains | 3 | 2009 | 112 | 0.040 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 3 | 2007 | 48 | 0.040 |
Why?
| | Interleukin-7 | 1 | 2019 | 61 | 0.040 |
Why?
| | ROC Curve | 1 | 2021 | 543 | 0.040 |
Why?
| | Hemorrhage | 1 | 1984 | 718 | 0.040 |
Why?
| | Lymphocytes | 1 | 2002 | 393 | 0.040 |
Why?
| | HLA-A Antigens | 2 | 2011 | 56 | 0.040 |
Why?
| | CD4-CD8 Ratio | 1 | 2019 | 22 | 0.040 |
Why?
| | Mice, Inbred BALB C | 4 | 2011 | 1271 | 0.040 |
Why?
| | Leg | 1 | 2001 | 223 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2023 | 744 | 0.040 |
Why?
| | Lymphopenia | 1 | 2019 | 61 | 0.040 |
Why?
| | Methylation | 1 | 2019 | 237 | 0.040 |
Why?
| | Databases, Factual | 1 | 2004 | 1345 | 0.040 |
Why?
| | Prospective Studies | 4 | 2016 | 7543 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 536 | 0.040 |
Why?
| | Postpartum Period | 1 | 2002 | 341 | 0.040 |
Why?
| | Seroconversion | 1 | 2018 | 46 | 0.040 |
Why?
| | Mucosal-Associated Invariant T Cells | 1 | 2018 | 27 | 0.040 |
Why?
| | Insulin Lispro | 3 | 2004 | 39 | 0.040 |
Why?
| | Meals | 1 | 2020 | 122 | 0.040 |
Why?
| | Macrophages | 2 | 1983 | 1547 | 0.040 |
Why?
| | Therapies, Investigational | 1 | 2018 | 17 | 0.040 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2018 | 11 | 0.040 |
Why?
| | B7-2 Antigen | 1 | 2017 | 27 | 0.040 |
Why?
| | Seroepidemiologic Studies | 1 | 2018 | 163 | 0.040 |
Why?
| | Wound Healing | 1 | 2001 | 327 | 0.040 |
Why?
| | Ikaros Transcription Factor | 1 | 2018 | 24 | 0.040 |
Why?
| | Colorado | 2 | 2024 | 4491 | 0.040 |
Why?
| | Glucose | 1 | 2023 | 1018 | 0.040 |
Why?
| | Cell Death | 1 | 2019 | 370 | 0.040 |
Why?
| | Aged | 7 | 2014 | 23641 | 0.030 |
Why?
| | Capsid | 2 | 1988 | 93 | 0.030 |
Why?
| | Patient Care Planning | 1 | 2018 | 154 | 0.030 |
Why?
| | Mice, Transgenic | 2 | 2018 | 2182 | 0.030 |
Why?
| | Drug Discovery | 1 | 2018 | 141 | 0.030 |
Why?
| | Rats | 3 | 1991 | 5675 | 0.030 |
Why?
| | Clone Cells | 3 | 2004 | 266 | 0.030 |
Why?
| | United States | 4 | 2015 | 14595 | 0.030 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2016 | 28 | 0.030 |
Why?
| | Structure-Activity Relationship | 2 | 2011 | 586 | 0.030 |
Why?
| | Antigens, CD | 2 | 2014 | 524 | 0.030 |
Why?
| | Genetic Markers | 1 | 1998 | 345 | 0.030 |
Why?
| | Twins | 1 | 2018 | 253 | 0.030 |
Why?
| | CD56 Antigen | 1 | 2016 | 36 | 0.030 |
Why?
| | Luminescent Measurements | 1 | 2017 | 76 | 0.030 |
Why?
| | Gene Expression Regulation | 3 | 2014 | 2615 | 0.030 |
Why?
| | Influenza A virus | 1 | 1997 | 109 | 0.030 |
Why?
| | Retrospective Studies | 4 | 2025 | 15514 | 0.030 |
Why?
| | Receptors, IgG | 1 | 2016 | 75 | 0.030 |
Why?
| | HLA-DQ beta-Chains | 2 | 2009 | 63 | 0.030 |
Why?
| | Leukocyte Common Antigens | 2 | 2007 | 87 | 0.030 |
Why?
| | Environment | 1 | 2018 | 362 | 0.030 |
Why?
| | Cell Count | 1 | 2017 | 321 | 0.030 |
Why?
| | Somalia | 1 | 2016 | 10 | 0.030 |
Why?
| | Antibody Specificity | 2 | 2007 | 189 | 0.030 |
Why?
| | Forecasting | 1 | 1998 | 386 | 0.030 |
Why?
| | Predictive Value of Tests | 2 | 2012 | 2030 | 0.030 |
Why?
| | Parasitemia | 1 | 1995 | 13 | 0.030 |
Why?
| | Orphan Drug Production | 1 | 2015 | 5 | 0.030 |
Why?
| | Organ Specificity | 2 | 2007 | 304 | 0.030 |
Why?
| | Radiation-Sensitizing Agents | 1 | 1995 | 42 | 0.030 |
Why?
| | Coloring Agents | 1 | 1995 | 86 | 0.030 |
Why?
| | Cities | 1 | 2016 | 132 | 0.030 |
Why?
| | Minnesota | 1 | 2016 | 161 | 0.030 |
Why?
| | Cohort Studies | 3 | 2015 | 5711 | 0.030 |
Why?
| | Transfusion Reaction | 1 | 1995 | 46 | 0.030 |
Why?
| | Chagas Disease | 1 | 1995 | 43 | 0.030 |
Why?
| | Immunity, Humoral | 1 | 2016 | 118 | 0.030 |
Why?
| | Intestines | 1 | 2018 | 356 | 0.030 |
Why?
| | Ethics, Medical | 1 | 2015 | 81 | 0.030 |
Why?
| | Immunity, Active | 1 | 2014 | 10 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2015 | 387 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2015 | 243 | 0.030 |
Why?
| | Transcription, Genetic | 4 | 1994 | 1458 | 0.030 |
Why?
| | Immunity, Innate | 2 | 2009 | 832 | 0.030 |
Why?
| | Proline | 1 | 1994 | 80 | 0.030 |
Why?
| | Opportunistic Infections | 1 | 2014 | 47 | 0.030 |
Why?
| | Immunoglobulins | 1 | 2014 | 171 | 0.030 |
Why?
| | Transplantation, Autologous | 1 | 2015 | 238 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2014 | 288 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 1995 | 1108 | 0.030 |
Why?
| | Drug Combinations | 1 | 2014 | 339 | 0.030 |
Why?
| | Protein Structure, Secondary | 1 | 1994 | 373 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2015 | 309 | 0.030 |
Why?
| | Sequence Deletion | 1 | 1994 | 183 | 0.030 |
Why?
| | Europe | 1 | 2014 | 413 | 0.030 |
Why?
| | Mutagenesis | 1 | 1994 | 182 | 0.030 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2013 | 41 | 0.030 |
Why?
| | Cost of Illness | 1 | 2015 | 302 | 0.030 |
Why?
| | Formamides | 1 | 1992 | 6 | 0.030 |
Why?
| | Interleukin-10 | 1 | 2015 | 302 | 0.030 |
Why?
| | Virus Replication | 3 | 1997 | 477 | 0.020 |
Why?
| | Body Mass Index | 1 | 2021 | 2351 | 0.020 |
Why?
| | Herpesviridae | 1 | 2012 | 23 | 0.020 |
Why?
| | Escherichia coli Proteins | 1 | 1994 | 195 | 0.020 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2015 | 544 | 0.020 |
Why?
| | Immunocompromised Host | 1 | 2014 | 203 | 0.020 |
Why?
| | Pregnancy | 2 | 2003 | 6715 | 0.020 |
Why?
| | Indoles | 1 | 1995 | 411 | 0.020 |
Why?
| | Renin | 1 | 2012 | 34 | 0.020 |
Why?
| | Interleukins | 1 | 2014 | 251 | 0.020 |
Why?
| | Postprandial Period | 1 | 2013 | 105 | 0.020 |
Why?
| | Influenza Vaccines | 1 | 1997 | 545 | 0.020 |
Why?
| | Lymph Nodes | 2 | 2006 | 493 | 0.020 |
Why?
| | RNA, Antisense | 1 | 1992 | 17 | 0.020 |
Why?
| | Virus Activation | 1 | 2012 | 89 | 0.020 |
Why?
| | Graft Survival | 1 | 2015 | 539 | 0.020 |
Why?
| | Herpesvirus 4, Human | 1 | 2012 | 167 | 0.020 |
Why?
| | HLA-B15 Antigen | 1 | 2011 | 13 | 0.020 |
Why?
| | Ligands | 2 | 2005 | 665 | 0.020 |
Why?
| | Proteomics | 1 | 2018 | 1111 | 0.020 |
Why?
| | Sample Size | 1 | 2011 | 118 | 0.020 |
Why?
| | Cognition Disorders | 1 | 2015 | 517 | 0.020 |
Why?
| | Societies, Medical | 1 | 2015 | 816 | 0.020 |
Why?
| | Thallium Radioisotopes | 1 | 1991 | 8 | 0.020 |
Why?
| | Phagocytosis | 2 | 1983 | 379 | 0.020 |
Why?
| | Receptors, Cell Surface | 2 | 1983 | 391 | 0.020 |
Why?
| | Vitamin D-Binding Protein | 1 | 2010 | 15 | 0.020 |
Why?
| | RNA Splicing | 1 | 1992 | 268 | 0.020 |
Why?
| | Small Molecule Libraries | 1 | 2011 | 96 | 0.020 |
Why?
| | Chronic Disease | 1 | 2017 | 1773 | 0.020 |
Why?
| | HLA-B8 Antigen | 1 | 2010 | 14 | 0.020 |
Why?
| | Isoantigens | 1 | 1990 | 15 | 0.020 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 55 | 0.020 |
Why?
| | Polymerase Chain Reaction | 2 | 2009 | 1061 | 0.020 |
Why?
| | Amino Acid Substitution | 2 | 2002 | 309 | 0.020 |
Why?
| | Rats, Inbred Strains | 1 | 1990 | 369 | 0.020 |
Why?
| | Spleen | 3 | 2002 | 516 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2010 | 268 | 0.020 |
Why?
| | Chemokines | 1 | 2010 | 229 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 401 | 0.020 |
Why?
| | Homozygote | 1 | 2009 | 203 | 0.020 |
Why?
| | Pedigree | 1 | 2010 | 509 | 0.020 |
Why?
| | Immunoblotting | 1 | 2009 | 307 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 1990 | 416 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2016 | 2844 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2009 | 240 | 0.020 |
Why?
| | Nausea | 1 | 2009 | 115 | 0.020 |
Why?
| | Logistic Models | 1 | 2014 | 2060 | 0.020 |
Why?
| | Vomiting | 1 | 2009 | 133 | 0.020 |
Why?
| | Interferon-alpha | 1 | 2009 | 198 | 0.020 |
Why?
| | Coronary Disease | 1 | 1991 | 385 | 0.020 |
Why?
| | Immunoglobulin M | 1 | 2009 | 287 | 0.020 |
Why?
| | Pseudomonas | 1 | 1988 | 31 | 0.020 |
Why?
| | Genetic Complementation Test | 1 | 1988 | 66 | 0.020 |
Why?
| | Genetic Vectors | 1 | 2009 | 322 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 1988 | 413 | 0.020 |
Why?
| | Codon | 1 | 1988 | 90 | 0.020 |
Why?
| | Exercise Test | 1 | 1991 | 621 | 0.020 |
Why?
| | Cell Line | 2 | 2004 | 2847 | 0.020 |
Why?
| | DNA Methylation | 1 | 2013 | 644 | 0.020 |
Why?
| | Fever | 1 | 2009 | 307 | 0.020 |
Why?
| | Immunotherapy, Adoptive | 1 | 1991 | 322 | 0.020 |
Why?
| | Up-Regulation | 1 | 2010 | 846 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 1988 | 434 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 1994 | 1502 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2009 | 208 | 0.020 |
Why?
| | Morphogenesis | 1 | 1988 | 166 | 0.020 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 84 | 0.020 |
Why?
| | Antisocial Personality Disorder | 1 | 1988 | 170 | 0.020 |
Why?
| | Age Distribution | 1 | 2007 | 391 | 0.020 |
Why?
| | NF-kappa B | 1 | 2010 | 685 | 0.020 |
Why?
| | Chromogranins | 1 | 2006 | 15 | 0.020 |
Why?
| | Models, Molecular | 1 | 2011 | 1586 | 0.020 |
Why?
| | Social Environment | 1 | 1988 | 305 | 0.020 |
Why?
| | Phosphorylation | 1 | 2010 | 1762 | 0.020 |
Why?
| | Mice, Inbred C3H | 2 | 1983 | 272 | 0.020 |
Why?
| | Psychotic Disorders | 1 | 1988 | 166 | 0.020 |
Why?
| | Hemodynamics | 1 | 1991 | 1114 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2007 | 765 | 0.010 |
Why?
| | Chemokine CXCL11 | 1 | 2005 | 3 | 0.010 |
Why?
| | Keratins | 1 | 2006 | 173 | 0.010 |
Why?
| | Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2005 | 15 | 0.010 |
Why?
| | Iodide Peroxidase | 1 | 2005 | 28 | 0.010 |
Why?
| | Glucagon | 1 | 2006 | 109 | 0.010 |
Why?
| | Thyroglobulin | 1 | 2005 | 27 | 0.010 |
Why?
| | Alprostadil | 1 | 2005 | 32 | 0.010 |
Why?
| | Chemokine CXCL9 | 1 | 2005 | 27 | 0.010 |
Why?
| | Mice, Inbred C57BL | 2 | 2011 | 5766 | 0.010 |
Why?
| | Chemokine CXCL10 | 1 | 2005 | 39 | 0.010 |
Why?
| | Lupus Coagulation Inhibitor | 1 | 1984 | 7 | 0.010 |
Why?
| | Antigenic Variation | 1 | 2004 | 10 | 0.010 |
Why?
| | Fathers | 1 | 2005 | 50 | 0.010 |
Why?
| | Dinoprostone | 1 | 2005 | 191 | 0.010 |
Why?
| | Interpersonal Relations | 1 | 1988 | 410 | 0.010 |
Why?
| | Mice, Inbred CBA | 1 | 2004 | 54 | 0.010 |
Why?
| | Tetanus Toxin | 1 | 2003 | 6 | 0.010 |
Why?
| | Infusion Pumps, Implantable | 1 | 2004 | 25 | 0.010 |
Why?
| | Chaperonin 60 | 1 | 2003 | 14 | 0.010 |
Why?
| | Insulin Aspart | 1 | 2004 | 27 | 0.010 |
Why?
| | Injections, Subcutaneous | 1 | 2004 | 154 | 0.010 |
Why?
| | Homeostasis | 1 | 2007 | 622 | 0.010 |
Why?
| | Quality of Life | 1 | 2015 | 2847 | 0.010 |
Why?
| | Indicators and Reagents | 1 | 1983 | 109 | 0.010 |
Why?
| | Escherichia coli | 1 | 1988 | 815 | 0.010 |
Why?
| | Fibrosis | 1 | 2006 | 552 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2015 | 2627 | 0.010 |
Why?
| | Biological Assay | 1 | 1983 | 123 | 0.010 |
Why?
| | Fetal Macrosomia | 1 | 2003 | 62 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1983 | 211 | 0.010 |
Why?
| | Models, Biological | 1 | 1990 | 1774 | 0.010 |
Why?
| | Antigens, CD1d | 1 | 2002 | 68 | 0.010 |
Why?
| | Congenital Abnormalities | 1 | 2003 | 87 | 0.010 |
Why?
| | C-Reactive Protein | 1 | 2005 | 409 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2004 | 784 | 0.010 |
Why?
| | Interleukin-2 | 1 | 2004 | 455 | 0.010 |
Why?
| | Antigens, Surface | 1 | 2002 | 154 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2010 | 1187 | 0.010 |
Why?
| | Antigens, Differentiation | 1 | 2002 | 83 | 0.010 |
Why?
| | Cell Division | 1 | 2004 | 795 | 0.010 |
Why?
| | Albuminuria | 1 | 2003 | 185 | 0.010 |
Why?
| | Sex Factors | 1 | 1988 | 2067 | 0.010 |
Why?
| | Celiac Disease | 1 | 2005 | 291 | 0.010 |
Why?
| | CTLA-4 Antigen | 1 | 2002 | 99 | 0.010 |
Why?
| | Temperature | 2 | 1997 | 680 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2006 | 1739 | 0.010 |
Why?
| | Alcoholism | 1 | 1988 | 798 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2005 | 1524 | 0.010 |
Why?
| | HLA-DQ alpha-Chains | 1 | 1999 | 16 | 0.010 |
Why?
| | Gestational Age | 1 | 2003 | 901 | 0.010 |
Why?
| | Birth Weight | 1 | 2003 | 514 | 0.010 |
Why?
| | Glutamine | 1 | 2000 | 104 | 0.010 |
Why?
| | Alanine | 1 | 2000 | 153 | 0.010 |
Why?
| | Substance-Related Disorders | 1 | 1988 | 1079 | 0.010 |
Why?
| | Aging | 2 | 2007 | 1863 | 0.010 |
Why?
| | Mothers | 1 | 2005 | 752 | 0.010 |
Why?
| | Incidence | 1 | 2005 | 2783 | 0.010 |
Why?
| | Mesocricetus | 1 | 1997 | 39 | 0.010 |
Why?
| | Cricetinae | 1 | 1997 | 288 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2005 | 3396 | 0.010 |
Why?
| | Chickens | 1 | 1997 | 192 | 0.010 |
Why?
| | Vaccines, Attenuated | 1 | 1997 | 129 | 0.010 |
Why?
| | Trifluoroethanol | 1 | 1994 | 1 | 0.010 |
Why?
| | Polydeoxyribonucleotides | 1 | 1994 | 14 | 0.010 |
Why?
| | Electrophoresis, Agar Gel | 1 | 1994 | 26 | 0.010 |
Why?
| | Sodium Dodecyl Sulfate | 1 | 1994 | 25 | 0.010 |
Why?
| | Transfection | 1 | 1997 | 948 | 0.010 |
Why?
| | Survival Rate | 1 | 1999 | 1972 | 0.010 |
Why?
| | Circular Dichroism | 1 | 1994 | 151 | 0.010 |
Why?
| | DNA, Single-Stranded | 1 | 1994 | 118 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 346 | 0.010 |
Why?
| | Genome, Viral | 1 | 1992 | 141 | 0.010 |
Why?
| | Radionuclide Imaging | 1 | 1991 | 119 | 0.010 |
Why?
| | Computer Simulation | 1 | 1994 | 984 | 0.010 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 1988 | 57 | 0.000 |
Why?
| | Neoplasms | 1 | 1983 | 2655 | 0.000 |
Why?
| | Lethal Dose 50 | 1 | 1983 | 15 | 0.000 |
Why?
| | Fibrosarcoma | 1 | 1983 | 22 | 0.000 |
Why?
| | Leukocytosis | 1 | 1983 | 31 | 0.000 |
Why?
| | Neoplasm Transplantation | 1 | 1983 | 256 | 0.000 |
Why?
| | Leukocyte Count | 1 | 1983 | 331 | 0.000 |
Why?
| | Dogs | 1 | 1983 | 411 | 0.000 |
Why?
| | Hypertension | 1 | 1991 | 1291 | 0.000 |
Why?
|
|
Gottlieb's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|